Huanjia Zhang
Articles Authored by Huanjia Zhang
ESHG: New Variant Analyses by Broad Institute Enhance Rare Disease Diagnostics
Analyzing data from the Broad's Center for Mendelian Genomics, researchers showed the diagnostic utility of exome CNVs and mitochondrial DNA variants.
ESHG: German Study Shows Utility of Rapid Whole-Genome Trio Sequencing in Critically Ill Children
Premium
Project Baby Lion diagnosed almost half of more than 60 critically ill children from a dozen German hospitals, with an average turnaround of under three days.
ESHG: UK 100K Genomes Project Demonstrates Diagnostic Potential of RNA-seq for Rare Diseases
Early analysis of transcriptomic sequencing data from over 4,400 rare disease patients revealed expression and splicing outliers that are likely disease-causing.
The Chinese firm has developed a genome engineering tool to precisely insert large DNA fragments into plant genomes in order to develop desirable traits in crops.
In addition to establishing local teams in Europe and China, the company recently inked distribution agreements for other markets across the world.
NanoString Reaffirms Revenue Guidance, Reassures Customers Following CosMx Injunction in Germany
Premium
In a call with investors on Monday, the Seattle-based spatial biology firm accused 10x Genomics of fearmongering aimed at NanoString's investors and customers.
Available in Q3, Sqk-RNA004 promises to have increased raw read accuracy and three times more data output compared to the existing RNA sequencing kit.
Based on direct nanopore sequencing, Nano-tRNAseq offers a potentially cost-effective tool to study tRNAs and their modifications without cDNA synthesis.
Hospital Surveillance Sequencing Helps Link Cases to Nationwide Contaminated Eyedrop Outbreak
Premium
University of Pittsburgh researchers detected two drug-resistant Pseudomonas aeruginosa infections using its healthcare pathogen whole-genome sequencing surveillance platform.
The optical genome mapping company announced a cost reduction plan that aims to cut expenditures by approximately $20.0 million over the next several quarters.